billing Latest news from Dana-Farber Cancer Institute on Newswise en-us Copyright 2025 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/cancer-vaccine-shows-promise-for-patients-with-stage-iii-and-iv-kidney-cancer/?sc=rsin /articles/cancer-vaccine-shows-promise-for-patients-with-stage-iii-and-iv-kidney-cancer/?sc=rsin Wed, 05 Feb 2025 11:30:51 EST Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine. Dana-Farber Cancer Institute /articles/ai-model-learns-generalized-language-of-regulatory-genomics-predicts-cellular-stories/?sc=rsin /articles/ai-model-learns-generalized-language-of-regulatory-genomics-predicts-cellular-stories/?sc=rsin Wed, 29 Jan 2025 19:20:19 EST A team of investigators from Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, Google, and Columbia University have created an artificial intelligence model that can predict which genes are expressed in any type of human cell. Dana-Farber Cancer Institute /articles/blood-test-could-guide-use-of-anti-inflammatory-drug-celecoxib-to-reduce-risk-of-colon-cancer-recurrence/?sc=rsin /articles/blood-test-could-guide-use-of-anti-inflammatory-drug-celecoxib-to-reduce-risk-of-colon-cancer-recurrence/?sc=rsin Sat, 25 Jan 2025 10:05:16 EST A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment. Dana-Farber Cancer Institute /articles/pet-probe-images-inflammation-with-high-sensitivity-and-selectivity/?sc=rsin /articles/pet-probe-images-inflammation-with-high-sensitivity-and-selectivity/?sc=rsin Wed, 22 Jan 2025 21:10:08 EST Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types. Dana-Farber Cancer Institute /articles/phase-2-litespark-003-results-suggest-continued-study-of-novel-first-line-combo-for-advanced-kidney-cancer/?sc=rsin /articles/phase-2-litespark-003-results-suggest-continued-study-of-novel-first-line-combo-for-advanced-kidney-cancer/?sc=rsin Fri, 17 Jan 2025 09:00:59 EST Current first-line treatment for advanced clear-cell renal cell carcinoma includes anti-PD1 or anti-PD-L1 immunotherapy in combination with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor such as cabozantanib. These options have improved outcomes in patients, however not all patients respond, and some responses do not last. This study's results suggest that further investigation of this novel combination as first-line therapy option is warranted. Dana-Farber Cancer Institute /articles/dana-farber-and-gustave-roussy-announce-2025-transatlantic-exchange-scientific-program-to-focus-on-radioligand-therapy/?sc=rsin /articles/dana-farber-and-gustave-roussy-announce-2025-transatlantic-exchange-scientific-program-to-focus-on-radioligand-therapy/?sc=rsin Mon, 13 Jan 2025 09:00:04 EST Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be "Radiopharmaceutical Therapy Meets Oncology." The meeting, supported by L'Institut Servier, will be held in-person on March 19, 2025, at Hyatt Regency Etoile Hotel and livestreamed. Dana-Farber Cancer Institute /articles/dana-farber-cancer-institute-delivers-simple-immediate-impact-to-patient-comfort-using-weighted-blankets/?sc=rsin /articles/dana-farber-cancer-institute-delivers-simple-immediate-impact-to-patient-comfort-using-weighted-blankets/?sc=rsin Fri, 04 Oct 2024 09:05:08 EST Weighted blankets are available to patients receiving infusions at all Dana-Farber locations as the result of a project led by staff nurse Cheri Hermann, BSN, RN, OCN. The initiative dates to March 2020, when she observed heightened anxiety in patients whose loved ones were unable to accompany them to appointments during the COVID-19 pandemic. Dana-Farber Cancer Institute /articles/dana-farber-cancer-institute-leads-the-launch-of-ignite-consortium-to-eradicate-health-inequities-in-pediatric-cancer-care/?sc=rsin /articles/dana-farber-cancer-institute-leads-the-launch-of-ignite-consortium-to-eradicate-health-inequities-in-pediatric-cancer-care/?sc=rsin Thu, 26 Sep 2024 09:30:57 EST In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE--the first national, pediatric hematology-oncology health equity research consortium. This groundbreaking initiative aims to eradicate inequities for children, adolescents, and young adults diagnosed with cancer or blood disorders via the rapid development and evaluation of policy-relevant, evidence-based and community informed health equity interventions. Dana-Farber Cancer Institute /articles/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2-positive-breast-cancer/?sc=rsin /articles/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2-positive-breast-cancer/?sc=rsin Fri, 13 Sep 2024 11:05:28 EST A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. Research led by Dana-Farber Cancer Institute. Dana-Farber Cancer Institute /articles/repeat-immune-checkpoint-inhibitor-therapy-not-recommended-for-advanced-kidney-cancer/?sc=rsin /articles/repeat-immune-checkpoint-inhibitor-therapy-not-recommended-for-advanced-kidney-cancer/?sc=rsin Fri, 13 Sep 2024 10:05:02 EST In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma. Dana-Farber Cancer Institute /articles/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024/?sc=rsin /articles/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024/?sc=rsin Wed, 11 Sep 2024 08:35:00 EST Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by Dana-Farber Cancer Institute and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Dana-Farber Cancer Institute /articles/antibody-drug-conjugate-highly-effective-in-preventing-recurrence-in-patients-with-early-stage-her2-breast-cancer-trial-finds/?sc=rsin /articles/antibody-drug-conjugate-highly-effective-in-preventing-recurrence-in-patients-with-early-stage-her2-breast-cancer-trial-finds/?sc=rsin Thu, 27 Jun 2024 16:00:00 EST * 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment * Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence Dana-Farber Cancer Institute /articles/researchers-report-first-effective-use-of-immunotherapy-for-most-common-subtype-of-colorectal-cancer/?sc=rsin /articles/researchers-report-first-effective-use-of-immunotherapy-for-most-common-subtype-of-colorectal-cancer/?sc=rsin Tue, 25 Jun 2024 13:05:23 EST These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination. Dana-Farber Cancer Institute /articles/anti-inflammatory-drug-celecoxib-could-reduce-risk-of-colon-cancer-recurrence-for-a-subset-of-patients/?sc=rsin /articles/anti-inflammatory-drug-celecoxib-could-reduce-risk-of-colon-cancer-recurrence-for-a-subset-of-patients/?sc=rsin Tue, 18 Jun 2024 16:00:00 EST An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation. Dana-Farber Cancer Institute /articles/new-guidelines-for-radiation-therapy-for-hpv-associated-head-and-neck-cancer/?sc=rsin /articles/new-guidelines-for-radiation-therapy-for-hpv-associated-head-and-neck-cancer/?sc=rsin Tue, 18 Jun 2024 11:05:00 EST New recommendations on the optimal use of radiation therapy for HPV-associated OPSCC are based on evidence from multiple clinical trials and aim to maintain good outcomes and reduce acute and late effects. Dana-Farber Cancer Institute /articles/telehealth-can-significantly-reduce-greenhouse-gas-emissions-associated-with-cancer-care-study-finds/?sc=rsin /articles/telehealth-can-significantly-reduce-greenhouse-gas-emissions-associated-with-cancer-care-study-finds/?sc=rsin Mon, 03 Jun 2024 09:05:56 EST Based on an analysis of data from a regional cancer center, Dana-Farber Cancer Institute researchers calculate that, nationwide, cancer care that utilizes telehealth and local care would generate 33.1% less greenhouse gas emissions than the traditional model of in-person care. Study published in JAMA Oncology. Dana-Farber Cancer Institute /articles/clinical-trials-show-promise-in-treating-central-nervous-system-lymphoma-breast-cancer-and-glioblastoma/?sc=rsin /articles/clinical-trials-show-promise-in-treating-central-nervous-system-lymphoma-breast-cancer-and-glioblastoma/?sc=rsin Sat, 01 Jun 2024 08:05:56 EST Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers. Dana-Farber Cancer Institute /articles/dana-farber-researchers-uncover-disparities-in-lived-experiences-for-patients-and-physicians/?sc=rsin /articles/dana-farber-researchers-uncover-disparities-in-lived-experiences-for-patients-and-physicians/?sc=rsin Thu, 30 May 2024 08:00:00 EST Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce. Dana-Farber Cancer Institute /articles/most-young-women-treated-for-breast-cancer-can-have-children-study-shows/?sc=rsin /articles/most-young-women-treated-for-breast-cancer-can-have-children-study-shows/?sc=rsin Thu, 23 May 2024 17:00:00 EST New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children. Dana-Farber Cancer Institute /articles/dana-farber-review-article-examines-past-and-guides-future-efforts-to-reduce-cancer-disparities/?sc=rsin /articles/dana-farber-review-article-examines-past-and-guides-future-efforts-to-reduce-cancer-disparities/?sc=rsin Mon, 06 May 2024 11:30:05 EST Investigators at Dana-Farber Cancer Institute have examined the historical evolution of Community Outreach and Engagement initiatives at both the National Cancer Institute (NCI) and National Cancer Institute-Designated Cancer Centers (NCI-DCCs). Dana-Farber Cancer Institute